Crenessity
Product Images NDC 70370-5250

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Crenessity (NDC 70370-5250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Neurocrine Biosciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Its Molecular Formula Is C27h28clfn2os, And Its Molecular Weight Is 483.04 G/mol With The Following Structure (Crenessity 01)

Chemical structure diagram of the active ingredient for Crenessity by Neurocrine Biosciences, Inc. The structure shows various rings, including a chlorine-substituted aromatic ring, a thiazole, and other functional groups, including an alkyne side chain.*

FDA Label Image

Figure A (Crenessity 02)

An instructional illustration showing the components of Crenessity oral solution packaging, including an oral solution bottle, an oral syringe labeled with cap (if applicable), tip, barrel, and plunger, and a press-in bottle adapter.*

FDA Label Image

Figure B (Crenessity 03)

An instructional line drawing showing hands opening a bottle by pressing down and turning the cap counterclockwise. The image is related to Crenessity by Neurocrine Biosciences, Inc., likely illustrating how to open the medication bottle safely.*

FDA Label Image

Figure C (Crenessity 04)

Illustration showing a hand removing a cap from a bottle, demonstrating how to open the bottle for access to its contents.*

FDA Label Image

Figure D (Crenessity 05)

An instructional line drawing showing a hand pressing down on a child-resistant closure cap to open a bottle. The diagram includes a close-up inset of the child-resistant cap mechanism on the bottle neck.*

FDA Label Image

Figure E (Crenessity 06)

An instructional illustration showing a hand holding a syringe with an arrow pointing upward, indicating the direction to pull or lift the syringe component. The image likely demonstrates part of the preparation or administration process for an injectable product.*

FDA Label Image

Figure F (Crenessity 07)

An instructional diagram showing a hand pressing down on a syringe plunger, directing liquid into a container below, with an arrow indicating the downward motion and another arrow showing the removal of the syringe from the container.*

FDA Label Image

Figure G (Crenessity 08)

An instructional illustration showing a hand holding a syringe or injection device above a vial. The image indicates the action of pushing the syringe downward into the vial, demonstrating the step of drawing liquid from the vial into the syringe for the drug Crenessity by Neurocrine Biosciences, Inc.*

FDA Label Image

Figure H (Crenessity 09)

An instructional illustration showing hands demonstrating how to open a bottle with a dropper. One hand holds the bottle steady, while the other hand unscrews the dropper cap by rotating it counterclockwise and lifting it up from the bottle.*

FDA Label Image

Figure I (Crenessity 0a)

An instructional illustration depicting a person using their fingers to open their mouth, showing hand positioning near the lips and teeth. The image likely demonstrates a technique related to medication administration or oral examination.*

FDA Label Image

Figure J (Crenessity 0b)

An instructional illustration showing two hands holding a syringe and needle under a faucet, demonstrating the process of rinsing or cleaning the syringe components with water.*

FDA Label Image

Principal Display Panelndc 70370-5025-1crenessity(crinecerfont) Capsules25 mg60 Capsulesrx Only (Crenessity 0c)

Crenessity 25 mg capsules packaging label showing the Neurocrine Biosciences, Inc. logo. The label states each capsule contains 25 mg of crinecerfont, includes storage instructions, a barcode, package quantity (60 capsules), and child-resistant packaging information. Distributed by Neurocrine Biosciences, Inc., San Diego, CA.*

FDA Label Image

Principal Display Panelndc 70370-5050-1crenessity(crinecerfont) Capsules50 mg60 Capsulesrx Only (Crenessity 0d)

Label for Crenessity capsules by Neurocrine Biosciences, Inc., containing 60 capsules. Each capsule contains 50 mg of crinecerfont. The label includes storage instructions, barcode, and child-resistant packaging notice.*

FDA Label Image

Principal Display Panelndc 70370-5100-1crenessity(crinecerfont) Capsules100 mg30 Capsulesrx Only (Crenessity 0e)

Label for Crenessity capsules containing 100 mg of crinecerfont. The label indicates a package size of 30 capsules and includes storage instructions (store at 15°C to 25°C, do not freeze). It notes the package is child-resistant and advises keeping out of reach of children. The label also features the Neurocrine Biosciences, Inc. logo and contact information for the distributor in San Diego, CA.*

FDA Label Image

Principal Display Panelndc 70370-5250-1crenessity(crinecerfont) Oral Solution50 mg/ml30 mLrx Only (Crenessity 0f)

Label for Crenessity oral solution by Neurocrine Biosciences, Inc., containing crinecerfont at a concentration of 50 mg/mL in a 30 mL bottle. The label includes storage instructions, dosage form (oral solution), and noted as prescription only for oral administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.